LYEL Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
Lyell Immunopharma, Inc. had $0.0M of revenue in fiscal 2025, down 41.0% on the year before. Over five years, revenue changed β65.9% a year on average.
Last close Β· Oct 23, 2026
$9.39
0.1%Hi! I read Lyell Immunopharma, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β41.0%
No. Sales fell 41.0% last year.
Does it make a profit?
β762,355.6%
No. It lost money last year.
Does profit turn into cash?
β418,900.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Lyell Immunopharma, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 12, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 12, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 12, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 11, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Lyell Immunopharma, Inc. had $0.0M of revenue in fiscal 2025, down 41.0% on the year before. Over five years, revenue changed β65.9% a year on average. Its operating margin was β748,344.4%, down 160,221.5Β pts: of every 100 in sales, about β748,344 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Lyell Immunopharma, Inc. lost $274M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$151M in fiscal 2025, β418,900.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Lyell Immunopharma, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $615M | $640M | $546M | $371M | $247M |
| Current ratio | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Quick ratio | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Total assets | $1.1B | $938M | $750M | $491M | $340M |
| Total liabilities | $198M | $104M | $95.1M | $108M | $91.9M |
| Shareholders' equity | $930M | $833M | $655M | $383M | $248M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Lyell Immunopharma, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 4 / 7 | 4 / 7 | 2 / 7 | 1 / 7 | 1 / 7 |
| Accruals ratio | β | β4.8% | β12.2% | β1.3% | β8.4% | β29.1% | β29.9% |
| Altman Z'' | β | β0.28 | 5.34 | 8.68 | 5.21 | β5.77 | β13.93 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $0.7M | $7.8M | $10.7M | $84.7M | $0.1M | $0.1M | $0.0M |
| Research and development | $63.6M | $182M | $139M | $159M | $183M | $172M | $159M |
| Operating income | β$102M | β$212M | β$215M | β$187M | β$247M | β$359M | β$269M |
| Income tax | β | β | β | β | β | β | $0.0M |
| Net income | β$129M | β$204M | β$250M | β$183M | β$235M | β$343M | β$274M |
| Net income to common | β$131M | β$208M | β$250M | β$183M | β | β | β |
| Diluted EPS | β$24.04 | β$15.69 | β$1.84 | β$0.74 | β$18.70 | β$26.23 | β$16.06 |
| Diluted shares | 0.00B | 0.01B | 0.14B | 0.25B | 0.01B | 0.01B | 0.02B |
| Cash flow | |||||||
| Cash from operations | $39.5M | β$161M | β$126M | β$170M | β$164M | β$162M | β$150M |
| Capital expenditure | $16.0M | $51.5M | $65.5M | $24.3M | $2.7M | $0.5M | $0.8M |
| Free cash flow | $23.4M | β$212M | β$192M | β$194M | β$166M | β$163M | β$151M |
| Depreciation and amortization | $1.3M | $4.3M | $13.6M | $18.0M | $20.3M | $19.6M | $11.5M |
| Stock-based compensation | $15.7M | $33.3M | $62.2M | $81.9M | $47.1M | $33.1M | $41.8M |
| Share buybacks | $0.2M | $11.8M | $0.0M | $0.0M | β | β | β |
| Dividends and buybacks | $0.2M | $11.8M | $0.0M | $0.0M | β | β | β |
| Balance sheet | |||||||
| Cash and short-term investments | $96.7M | $613M | $615M | $640M | $546M | $371M | $247M |
| Current assets | β | $618M | $626M | $651M | $555M | $380M | $261M |
| Current liabilities | β | $49.3M | $46.7M | $37.0M | $34.5M | $53.8M | $49.4M |
| Property and equipment, net | β | $77.0M | $120M | $123M | $103M | $48.2M | $34.8M |
| Total assets | β | $908M | $1.1B | $938M | $750M | $491M | $340M |
| Total liabilities | β | $190M | $198M | $104M | $95.1M | $108M | $91.9M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$111M | β$293M | $930M | $833M | $655M | $383M | $248M |
| Margins | |||||||
| Operating margin | β15,538.7% | β2,732.6% | β2,016.7% | β220.9% | β190,006.2% | β588,123.0% | β748,344.4% |
| EBITDA margin | β15,347.5% | β2,677.2% | β1,888.8% | β199.6% | β174,429.2% | β555,941.0% | β716,291.7% |
| Net margin | β19,692.1% | β2,636.3% | β2,349.5% | β216.2% | β180,486.2% | β562,285.2% | β762,355.6% |
| FCF margin | 3,565.8% | β2,737.9% | β1,800.5% | β228.9% | β127,984.6% | β266,980.3% | β418,900.0% |
| Returns | |||||||
| Return on capital employed | β | β24.7% | β19.9% | β20.8% | β34.5% | β82.1% | β92.7% |
| Return on equity | β | β | β78.5% | β20.8% | β31.5% | β66.1% | β87.0% |
| Return on assets | β | β22.5% | β24.6% | β17.7% | β27.8% | β55.3% | β66.1% |
| Return on tangible equity | β | β | β26.9% | β22.0% | β35.8% | β89.6% | β110.6% |
| Growth | |||||||
| Revenue growth | β | 1,080.5% | 37.3% | 695.1% | β99.8% | β53.1% | β41.0% |
| FCF growth | β | β1,006.5% | β | β | β | β | β |
| Share count change | β | 245,418.5% | 925.2% | 81.8% | β94.9% | 4.2% | 30.7% |
| Financial health | |||||||
| Current ratio | β | 12.5x | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Quick ratio | β | 12.5x | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Capital allocation | |||||||
| Capex / revenue | 2,442.5% | 663.8% | 615.1% | 28.7% | 2,066.2% | 760.7% | 2,166.7% |
| Stock comp / revenue | 2,394.5% | 428.8% | 584.0% | 96.7% | 36,218.5% | 54,334.4% | 116,191.7% |
| Payouts / FCF | 0.8% | β | β | β | β | β | β |
| Quality scores | |||||||
| Piotroski F-score | β | β | 4.0 | 4.0 | 2.0 | 1.0 | 1.0 |
| Altman Z'' | β | β0.3 | 5.3 | 8.7 | 5.2 | β5.8 | β13.9 |
| Accruals ratio | β | β4.8% | β12.2% | β1.3% | β8.4% | β29.1% | β29.9% |
Source: SEC EDGAR XBRL filings (CIK 0001806952). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
